Absci Investor Relations Material

Absci Corporation operates as a generative AI drug creation company, focusing on revolutionizing the process of biologics drug discovery. Leveraging an integrated drug creation platform, Absci identifies novel drug targets and creates biotherapeutic candidates, shifting from traditional drug discovery to drug creation. This approach enables the design of de novo antibodies directly on computers, potentially reducing the development time for new drug leads and increasing their probability of success. The company's platform combines artificial intelligence with synthetic biology, allowing the construction and testing of millions of AI designs weekly. This innovative process results in wet lab-validated biologic-based therapeutics in a significantly shortened timeframe, aiming to address the challenges of traditionally high failure rates and lengthy development times in biologics drug discovery. The company is headquartered in Vancouver, Washington, and its shares are listed on the Nasdaq.